148596-90-1

Basic information

• Product Name: 21-Hydroxy DeschloroMoMetasone Furoate (IMpurity)
• Synonyms: 21-Hydroxy DeschloroMoMetasone Furoate (IMpurity);21-Dechloro-21-Hydroxy Mometasone Furoate;Mometasone Furoate EP Impurity H
• CAS NO: 148596-90-1
• Molecular Formula: C27H31ClO7
• Molecular Weight: 502.98384
• Product Categories: Metabolites and Impurities, Pharmaceuticals, Intermediates & Fine Chemicals
• Mol File: 148596-90-1.mol
• Article Data: 1

Chemical Properties

• Appearance: /
• Storage Temp.: Refrigerator
• Solubility: DMSO (Slightly), Methanol (Slightly)
• CAS DataBase Reference: 21-Hydroxy DeschloroMoMetasone Furoate (IMpurity)(CAS DataBase Reference)
• NIST Chemistry Reference: 21-Hydroxy DeschloroMoMetasone Furoate (IMpurity)(148596-90-1)
• EPA Substance Registry System: 21-Hydroxy DeschloroMoMetasone Furoate (IMpurity)(148596-90-1)

Safety Data

• Hazardous Substances Data: 148596-90-1(Hazardous Substances Data)

Usage

Chemical Properties

White to Off-White Solid

Uses

Different sources of media describe the Uses of 148596-90-1 differently. You can refer to the following data:
1. 21-Hydroxy Deschloromometasone Furoate (Mometasone EP Impurity H) is an impurity of Mometasone Furoate (M490000), a topical corticosteroid used as an anti-inflammatory.
2. (21-Hydroxy Deschloromomtasone Furoate) Impurity of Mometasone Furoate (M490000), a topical corticosteroid used as an anti-inflammatory.

Upstream product

• 10106-41-9 17α,21-dihydroxy-16α-methyl-1,4,9(11)-pregnatriene-3,20-dione 21-acetate 
• 83897-05-6 9α-chloro-16α-methyl-11β,17α,21-trihydroxy-1,4-pregnadiene-3,20-dione 17-(2'-furoate) 21-acetate 
• 83880-61-9 16α-methyl-17α,21-dihydroxy-1,4,9(11)-pregnatriene-3,20-dione 17-(2'-furoate) 21-acetate 

Relevant articles and documents

Improvements in corticosteroid 21-acetoxy-17α-hydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione synthesis and its use as common intermediate in the synthesis of some impurities related to dexamethasone and mometasone

There are quite substantial number of impurities related to dexamethasone or mometasone which cannot be made from respective Active Pharmaceutical Ingredients but from common intermediate 21-acetoxy-17α-hydroxy-16α-methyl-pregna-1,4,9(11)-triene-3,20-dione (12). As such, a robust and economical synthesis of this key intermediate is important for delivering a resilient and economically viable supply chain for these impurities. Therefore, it is critical to have a robust and economically viable process to synthesize the intermediate 12 in good yield and quality. We report here an improved synthesis of 12 and eight impurities related to dexamethasone and mometasone from this common intermediate.